Jomed chooses to avoid US patent fight with Cordis
This article was originally published in Clinica
Executive Summary
Jomed, a European-based medical technology company which is attempting to launch its Jostent stent graft into the US has made a comprehensive licence agreement with the Cordis division of Johnson & Johnson, covering a number of Cordis' balloon expandable stent patents. Its decision means that Jomed has avoided an expensive and drawn out fight in the US courts.
You may also be interested in...
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.